A new dual PPARα and PPARγ agonist known as Saroglitazar, with a higher activity for PPARα and moderate PPARγ activity, has been approved for the treatment of type 2 diabetes in India in order to control diabetic dyslipidemia [102]. Here, PPARA is linked to type 2 diabetes mellitus.